Proactive Investors - Run By Investors For Investors

LeanLife Health hires strategic advisor

LeanLife Health announced Monday it has brought Russ Hiebert on board as a strategic advisor
flax seeds
LeanLife Health's products are extracted from flax, which is a common and non-animal source of omega-3

LeanLife Health Inc (CSE:LLP) announced Monday it has brought Russ Hiebert on board as a strategic advisor.

Hiebert has significant experience in government, developing trade and corporate governance.

Hiebert was a member of Parliament in Canada for 11 years (2004-2015) and then returned to the private sector. During his time in office, he was appointed parliamentary secretary for Defense and later parliamentary secretary for Intergovernmental Affairs. He also served on the natural resources, finance and international trade committees.

READ: LeanLife closes first round of financing: raises $750,000

"Russ Hiebert brings valuable resources and substantial experience to LeanLife," said Stan Lis, chief executive officer of LeanLife Health.

"I look forward to working with the LeanLife Health team to help realize the value of extracting shelf-stable omega-3 fatty acids from flax seed -- one of the richest plant sources of this essential fatty acid. The long-lasting shelf life of the flax seed oil produced by LeanLife's patented method appears to make it an ideal fortified food ingredient," said Hiebert.

Hiebert has developed a worldwide network of contacts in business and foreign governments with the ability to connect people with key decision makers, joint venture partners and investors, for the purpose of developing trade and other business opportunities.

Contact Katie Lewis at [email protected]

Follow her on Twitter: @kelewis

View full LLP profile View Profile

LeanLife Health Timeline

February 07 2019

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use